In section Market Quotes

Keros Shares Rise 11% After $5 Million Buyback Approval

Keros Therapeutics shares climbed 11% to $11.12 on Tuesday after the company’s board approved a share repurchase program of up to $5 million. The gain followed a $20 million development milestone payment from Takeda Pharmaceuticals under a licensing agreement.

Keros Shares Rise 11% After $5 Million Buyback Approval

The clinical-stage biopharmaceutical company said the payment relates to elritercept, a drug now being tested in a clinical trial. Keros recently completed the first dosing of a patient in the trial.

Despite Tuesday’s rise, the stock remains down 45% this year.

Share:on TelegramXFacebook

Subscribe to our newsletter

Once a week — the best stories from our editors, no ads or push notifications. Delivered Sunday morning.

Comments (0)

Leave a comment

No comments yet. Be the first!